A competent authority flags a gap in your technical documentation, or notices your Basic UDI-DI was never correctly assigned. The instinct on most quality teams is to brace for the MDR's recall machinery — Article 95's procedure for devices presenting an unacceptable risk. Most of the time, that is the wrong article. Article 97 — "other non-compliance" — is where findings that do not clear the unacceptable-risk bar actually live, and it works on a different logic: a remediation period, not a withdrawal order.

Two tracks, one trigger: the risk test

Chapter VII of the MDR gives competent authorities more than one lever once they conclude a device does not meet the regulation's requirements. The branch point is a single question: does the non-compliance present an unacceptable risk to health, safety, or the environment? A yes routes the case to Article 95's procedure, built around withdrawal, recall, and restricting market access. A no routes it to Article 97, built around giving the manufacturer or its authorized representative a period to bring the non-compliance to an end. The two articles are not alternative strategies a manufacturer gets to pick between — they describe what the authority does once it has made that risk determination, and an authority that starts on the Article 97 track can move a case to Article 95 if new information changes the answer.

Art. 97
MDR's non-risk non-compliance procedure — a remediation period, not a recall.
Art. 95
The parallel procedure for devices presenting an unacceptable risk — this is the one that leads to withdrawal.
ONC
The EUDAMED procedure code competent authorities use to log and share Article 97 cases with other member states.

What tends to land here

The MDR does not hand Article 97 a tidy list of qualifying non-compliances — the test is the risk determination, not a category. In practice, the gaps that land here are the administrative and documentation failures that post-market reporting and notified body surveillance most often surface: incomplete or outdated technical documentation, a UDI assignment or database entry that was never corrected, a CE marking irregularity, an EU declaration of conformity that does not match the device on the market, or a gap in the authorized representative or PRRC designation. None of these, on their own, say anything about whether the device performs safely in a patient. That is exactly why they sit on the Article 97 side of the line — and exactly why a quality team that treats every finding as an Article 95-grade emergency ends up over-escalating internally while under-documenting the thing that actually needs fixing.

The risk test is the authority's determination, built on its own assessment — not a label a manufacturer gets to attach to make a finding feel smaller. Why self-assessment isn't the same as the authority's determination

The legacy-device case MDCG 2022-18 actually covers

Article 97 got unusual visibility through MDCG 2022-18, a position paper addressing one specific scenario: a manufacturer whose MDD or AIMDD certificate expires before its MDR certificate is issued — a timing gap, not a safety finding. The guidance describes member states generally not extending that relief beyond twelve months, and a later addendum narrowed its use to very exceptional situations. That guidance is a single application of Article 97, not a redefinition of it, and teams that have only encountered the article through legacy-certificate conversations sometimes assume it is a legacy-only mechanism. It isn't. The underlying procedure — non-compliance, no unacceptable risk, a proportionate remediation period — applies to the documentation and labeling gaps a quality and compliance program surfaces in any given year, legacy device or not.

  • The request runs through the authority, not around it. A manufacturer or its authorized representative proactively notifies the competent authority and gets a written response before relying on an Article 97 allowance — it is not a self-declared grace period.
  • Other member states find out. The authority that grants the allowance is required to inform the other EU competent authorities — the case does not stay local, and a later inspection elsewhere can reference it.
  • Market surveillance doesn't pause. Article 97 relief does not exempt the manufacturer or any other economic operator from the rest of the MDR's market surveillance activity while the remediation runs.
  • The clock is proportionate, not standard. Treat any period you are given as specific to your case's facts — not as a benchmark the next finding can assume it will also get.
Before you assume the article you're under
  1. Get the risk determination in writing. Confirm explicitly that the authority has placed the case on the Article 97 track, rather than inferring it from the tone of a first letter.
  2. Separate the finding from the fix. Scope exactly which requirement is unmet before proposing remediation — a vague corrective action invites a broader review.
  3. Propose your own timeline. A specific, justified remediation plan is more likely to set the proportionate period than silence is.
  4. Assume visibility beyond your market. Document the case as though every EU competent authority will eventually see it — because the regulation says they will.

EUDAMED's market surveillance module, now part of the set that became mandatory under the EUDAMED mandatory-use timeline, is where Article 97 cases get logged under the "other non-compliance" procedure type — which means the administrative gap you close quietly this quarter is no longer the kind of thing that stays quiet. A documentation finding handled well under Article 97 closes as a footnote. One handled as if the distinction between the two articles didn't matter — over-escalated internally, under-documented externally — is the kind of footnote that gets read again at the next notified body audit.

Frequently asked questions

What is the difference between MDR Article 95 and Article 97?

Article 95 governs devices a competent authority has assessed as presenting an unacceptable risk to health, safety, or the environment — it leads toward withdrawal, recall, or market restriction. Article 97 covers everything else: a device that fails to meet an MDR requirement — documentation, labeling, UDI, CE marking — without presenting that unacceptable risk. If an authority working an Article 97 case later concludes the risk test is met, it moves the case to Article 95 instead.

Does Article 97 apply only to legacy devices?

No. The article is a general non-compliance procedure. It has drawn particular attention through MDCG 2022-18, which applies it to a specific legacy-device scenario — a manufacturer whose MDD or AIMDD certificate expires before its MDR certificate issues — but that guidance is one application of the article, not its scope.

How long does a manufacturer get to fix an Article 97 finding?

The MDR requires the competent authority to set a period proportionate to the non-compliance; it does not fix a universal number of days. In the legacy-device scenario MDCG 2022-18 addresses, the guidance describes authorities generally not extending more than twelve months, and a later addendum limits that specific use to very exceptional situations. Treat any duration as case-specific rather than as a guaranteed window.

Sources & further reading

  1. Regulation (EU) 2017/745 (MDR), consolidated text. Article 97, Other non-compliance. eur-lex.europa.eu
  2. Medical Device Coordination Group. MDCG 2022-18 — Position Paper on the application of Article 97 MDR to legacy devices for which an MDD/AIMDD certificate expires before issuance of an MDR certificate (9 Dec. 2022). health.ec.europa.eu

This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm the current text of MDR Article 97 and any applicable MDCG guidance with your notified body, competent authority, or qualified counsel before acting.